Easywell Biomedicals Inc.
Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in America. It operates through Drug Development and Other segments. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and … Read more
Easywell Biomedicals Inc. (1799) - Total Liabilities
Latest total liabilities as of June 2024: NT$653.80 Million TWD
Based on the latest financial reports, Easywell Biomedicals Inc. (1799) has total liabilities worth NT$653.80 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Easywell Biomedicals Inc. - Total Liabilities Trend (2019–2023)
This chart illustrates how Easywell Biomedicals Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Easywell Biomedicals Inc. Competitors by Total Liabilities
The table below lists competitors of Easywell Biomedicals Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NewFlex Technology Co. Ltd
KQ:085670
|
Korea | ₩55.95 Billion |
|
Kellton Tech Solutions Limited
NSE:KELLTONTEC
|
India | ₹2.21 Billion |
|
Neo Battery Materials Ord Shs
V:NBM
|
Canada | CA$1.16 Million |
|
Minsud Resources Corp
PINK:MDSQF
|
USA | $233.49K |
|
Hafnia Limited
NYSE:HAFN
|
USA | $1.24 Billion |
|
Daldrup & Söhne Aktiengesellschaft
F:4DS
|
Germany | €11.69 Million |
|
Maisons du Monde S.A
PINK:MDOUF
|
USA | $1.03 Billion |
|
Liquidmetal Technologies Inc
OTCQB:LQMT
|
USA | $1.41 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down Easywell Biomedicals Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Easywell Biomedicals Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Easywell Biomedicals Inc. (2019–2023)
The table below shows the annual total liabilities of Easywell Biomedicals Inc. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$589.99 Million | +46.55% |
| 2022-12-31 | NT$402.60 Million | +14.43% |
| 2021-12-31 | NT$351.82 Million | +2.21% |
| 2020-12-31 | NT$344.19 Million | -27.79% |
| 2019-12-31 | NT$476.69 Million | -- |